Boehringer Ingelheim has announced the launch of the GLORIA-AF registry programme, which is set to understand the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation-related stroke in a real-world setting.
With up to 56,000 patients planned for enrolment across 2,200 sites in 50 countries, GLORIA-AF will study treatment regimes available for stroke prevention in non-valvular AF and respective patient outcomes. The registry programme will collect important data on the safety and comparative effectiveness of antithrombotic treatments, including vitamin K antagonist warfarin, acetylsalicylic acid and novel oral anticoagulants, such as dabigatran etexilate.
“With novel oral anticoagulants entering the market having shown convincing clinical trial data in the prevention of stroke in non-valvular AF, registries such as GLORIA-AF are important in investigating how these trial results translate into clinical practice, and provide insight into how antithrombotic therapy can be fully optimised to ensure patients with AF at risk of stroke receive the best possible care,” said Menno Huisman, associate professor at Leiden University Medical Center, Department of Thrombosis and Haemostasis, The Netherlands and chair of the GLORIA-AF registry programme.
To mirror the real-world setting, GLORIA-AF will involve a range of clinical settings including general practices, specialist offices, community hospitals, university hospitals, outpatient care centres and anticoagulation clinics. By 2012, the registry will have started in countries of all major regions of the world, including USA, EU, Latin America and Asia with other participating countries following subsequently and completion anticipated by 2020.
“The launch of the GLORIA-AF registry programme is exciting news and a really important step forward,” said Eve Knight co-founder and chief executive of AntiCoagulation Europe, UK. “Given that AF is the most common sustained heart rhythm condition affecting over 70 million people worldwide and is associated with raising the risk of someone with AF having a stroke by five times, it is incredibly important to find out how effective and safe both old and new treatments are in protecting people from a potentially disabling and deadly stroke.”
Gregory Lip, professor of Cardiovascular Medicine at University of Birmingham Centre for Cardiovascular Sciences, UK said, “GLORIA-AF is a truly collaborative effort, which brings together leading experts from a number of therapy areas across the globe to gain insights into the changing landscape of stroke prevention in non-valvular AF. It is with excitement that we are anticipating presenting more details about the unique design of this registry programme later in 2012.”